# Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

> **NCT06850090** · PHASE3 · RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 210 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Cancer Patients

## Interventions

- **COMBINATION_PRODUCT:** TAS-102
- **COMBINATION_PRODUCT:** Capecitabine

## Key facts

- **NCT ID:** NCT06850090
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850090, "Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06850090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*